Skip to content
value.today

QR Pharma, Inc.

Total raised
$1 M
1 round on record
Latest round
$1 M
May 2015
First round on record
May 2015
Today
Went public
See the company page

QR Pharma, Inc. is listed today as Annovis Bio, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of QR Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2023$1 MPrivate placement after listingUnder $2 million

QR Pharma, Inc.: Private sale, Apr 2023

Investors in this round

6 investors had bought by the notice of Apr 25, 2023: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for QR Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Henry Hagopian · Executive Officer · Chief Financial Officer
  • Maria Maccecchini · Executive Officer, Director · Chief Executive Officer
  • Claudine Bruck · Director
  • Mark White · Director
  • Michael Hoffman · Director
  • Reid McCarthy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Henry Hagopian III, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 25, 2023. Read the notice at the SEC.

equitySEC
May 2015$1 MNo. 1Under $2 million

QR Pharma, Inc.: Raise no. 1, May 2015

Investors in this round

21 investors had bought by the notice of Jun 5, 2015: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for QR Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$120,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Maria Maccecchini · Executive Officer, Director
  • Dhesh F. Govender · Director
  • Franz F. Hefti · Director
  • Michael Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Does not include proceeds of Convertible Promissory Notes that were converted in the offering.”

Signed by Maria L. Maccecchini, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 5, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • QR Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2023).

    SEC Form D · Apr 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2023

That is all the official record says: QR Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of QR Pharma, Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in QR Pharma, Inc.
InvestorKindAmountRoundRoleSource
Claudine BruckPersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2020)SEC Form 3
Maria-Luisa MaccecchiniPersonnot statednot statedHeld Series A and A-1 preferred stock, director (Form 3, 2020)SEC Form 3
Mark K. WhitePersonnot statednot statedHeld Series A and A-1 preferred stock, director (Form 3, 2020)SEC Form 3
Michael B. HoffmanPersonnot statednot statedHeld Series A and A-1 preferred stock, director (Form 3, 2020)SEC Form 3
Robert M. Whelan Jr.Personnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 21 investors.

Largest shareholders today

Institutions holding Annovis Bio, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by QR Pharma, Inc.
NameRoleNamed in
Henry HagopianChief Financial OfficerApr 2023
Maria MaccecchiniChief Executive OfficerApr 2023
Claudine BruckDirectorApr 2023
Maria MaccecchiniChief Executive OfficerApr 2023
Mark WhiteDirectorApr 2023
Michael HoffmanDirectorApr 2023
Reid McCarthyDirectorApr 2023
Dhesh F. GovenderDirectorJun 2015
Franz F. HeftiDirectorJun 2015

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.